Abstract : Adults and elderly patients suffering from RVI including that of corona and influenza viruses’ outbreaks, developed severe complications caused by a bacterial co-infection leading to pneumonia, resulting in man death. Some people are vulnerable to develop complications. WHO states that bacterial pneumonia post-RVI elevated mortality up to 38%. However, these complications were not the case in children. Statistical studies showed that pneumoniae was mainly caused by the bacterium S. pneumoniae, that can be detected more in children than adults. In contrast, investigation of infected patients illustrated that children showed no clinical complications post-RVI. Interestingly, in the first two years after birth, children receive 4 doses of PCV13 as declared by Centers for Disease Control and Prevention (CDC). Hence, based on available global data, this perspective suggests that the PCV could ease in protecting victims of RVI, not only with COVID-19, but also with other future emerging human respiratory viruses